Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 17/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 13/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 13/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7246889 | 0.88 | ADRA1A (0.60) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7236482 | 0.85 | ADRA1A (0.55) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7952573 | 0.80 | ADRA1A (0.74) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7246347 | 0.80 | ADRA1A (0.57) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7242493 | 0.78 | ADRA1A (0.60) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL9392170 | 0.78 | ADRA1A (0.69) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7245997 | 0.78 | ADRA1A (0.55) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7237001 | 0.77 | ADRA1A (0.60) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7954084 | 0.76 | ADRA1A (0.56) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7690732 | 0.76 | ADRA1A (0.51) | ADRA1AADRA1DADRA1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608086-B2 | Selective adrenergic receptor alpha 1C antagonists without significant calcium channel activity; treating benign prostatic hyperplasia, intraocular pressure and inhibiting cholesterol synthesis | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193599-A1 | Dihydropyridines and new uses thereof | BPHL, BCKDK, DHCR7 | ADRA1A 73/4885ADRA1D 77/4885ADRA1B 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.